Compass Pathways (CMPS) Stock Price, News & Analysis

Company Overview

Compass Pathways plc is a biotechnology company developing psychedelic treatments for mental health conditions. The company’s lead investigational product is COMP360, a proprietary formulation of synthetic psilocybin administered with psychological support in a controlled clinical setting.

Compass Pathways has focused primarily on treatment-resistant depression, a condition in which patients do not achieve adequate relief from standard therapies. Its research has also explored the potential use of COMP360 in other serious mental health disorders. COMP360 is an investigational therapy and has not been approved for commercial use by regulatory authorities.

Founded in 2016, Compass Pathways is headquartered in London and has conducted clinical development activities in the United States, the United Kingdom and other European countries. The company’s leadership includes Chief Executive Officer Kabir Nath, who joined Compass Pathways after holding senior positions in the biopharmaceutical industry.

Key Stats

• Today's Range: $11.13 to $11.54
• 50-Day Range: $11.47 to $15.19
• 52-Week Range: $4.88 to $15.87
• Volume: 1.26 million shs
• Average Volume: 3.48 million shs
• Market Capitalization: $1.56 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $23.36
• Consensus Rating: Moderate Buy

Compass Pathways Stock Analysis - MarketRank™

Compass Pathways scored higher than 53% of companies evaluated by MarketBeat, and ranked 552nd out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Compass Pathways has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 1 strong buy rating, 14 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Compass Pathways has a consensus price target of $23.36, representing about 109.1% upside from its current price of $11.17.

Amount of Analyst Coverage

Compass Pathways has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Compass Pathways are expected to decrease in the coming year, from ($1.26) to ($1.87) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Compass Pathways is -2.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Compass Pathways is -2.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.66% of the float of Compass Pathways has been sold short.

Short Interest Ratio / Days to Cover

Compass Pathways has a short interest ratio ("days to cover") of 5.87.

Change versus previous month

Short interest in Compass Pathways has recently increased by 11.81%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Compass Pathways does not currently pay a dividend.

Dividend Growth

Compass Pathways does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: N/A

News Sentiment

Compass Pathways has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Compass Pathways this week, compared to 5 articles on an average week.

Search Interest

Only 18 people have searched for CMPS on MarketBeat in the last 30 days. This is a decrease of -10% compared to the previous 30 days.

MarketBeat Follows

10 people have added Compass Pathways to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Compass Pathways insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.82% of the stock of Compass Pathways is held by insiders.

Percentage Held by Institutions

46.19% of the stock of Compass Pathways is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 10/13/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:CMPS
• CIK: 1816590
• Web: www.compasspathways.com
• Phone: 716-676-6461
• Fax: N/A
• Employees: 156
• Year Founded: 2016

Price Target and Rating

• Average Price Target for Compass Pathways: $23.36
• High Price Target: $65.00
• Low Price Target: $13.00
• Potential Upside/Downside: +108.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.88
• Research Coverage: 17 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.62)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$287.86 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -49.63%
• Return on Assets: -13.08%

Debt

• Debt-to-Equity Ratio: 0.60
• Current Ratio: 1.30
• Quick Ratio: 1.30

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.55) per share
• Price / Book: -20.35

Miscellaneous

• Outstanding Shares: 138,480,000
• Free Float: 134,572,000
• Market Cap: $1.55 billion
• Optionable: Optionable
• Beta: 2.55